ESMO: CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
No standard treatment has been defined yet for second- or third-line systemic treatment of...
Read MoreSep 24, 2020
No standard treatment has been defined yet for second- or third-line systemic treatment of...
Read MoreSep 24, 2020
According the primary results of the COMBI-i trial, the addition of PD1 inhibitor spartalizumab to...
Read MoreSep 23, 2020
Addition to chemotherapy may set a new Standard Immunotherapy for patients with high-risk gastric...
Read MoreSep 22, 2020
The 8th Joint ACTRIMS-ECTRIMS meeting – the largest international conference focused on research...
Read MoreSep 19, 2020
Thank you for taking our quiz on PsA from results presented at ACR Convergence 2020! How did you do? 1) DMARD-naïve patients achieving Routine Assessment of Patient Index Data 3 (RAPID3) and the Clinical Disease Activity for...
Read MoreSep 17, 2020
The ESMO Virtual Congress 2020, September 19-21, will present promising new developments aimed at...
Read MoreSep 17, 2020
Two sets of CNS efficacy data from integrated analyses of the pivotal phase II STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented, including a poster presentation evaluating the efficacy of...
Read MoreSep 17, 2020
Results from an exploratory analysis of characterization of long-term survivors (LTS), defined in the study as people who survived for longer than 18 months following randomization, in the IMpower133 trial will be presented in a...
Read MoreSep 17, 2020
Thyroid AEs did not diminish alemtuzumab efficacy Adverse thyroid events occur frequently among...
Read MoreSep 17, 2020
Safety modeling favors ozanimod Patients diagnosed with multiple sclerosis appear to have fewer...
Read MoreSep 17, 2020
final data from the FORWARD II triplet cohort evaluating mirvetuximab soravtansine in combination with carboplatin and bevacizumab (Avastin® )in patients with folate receptor alpha (FRα)-positive recurrent, platinum-sensitive...
Read MoreSep 16, 2020
Benefit observed in patients with or without disease activity Among multiple sclerosis patients...
Read MoreSep 9, 2020
Efficacy results from the Phase IV MAGNIFY-MS study and its impact on a reduction in mean combined...
Read MoreSep 9, 2020
MSVirtual2020, the 8th Joint Americas Committee for Treatment and Research in Multiple Sclerosis...
Read MoreSep 9, 2020
New efficacy and safety data on ofatumumab (Kesimpta), the first and only self-administered,...
Read MoreSep 9, 2020
Health Union has been accepted to present research, in the form of two poster presentations,...
Read MoreSep 9, 2020
This year, MSVirtual2020 (ACTRIMS/ECTRIMS) congress will feature new data relating to tolebrutinib...
Read MoreSep 9, 2020
Download the MSVirtual2020 Program at a Glance schedule (PDF)
Read MoreSep 2, 2020
As researchers tout outcomes, Rx lags and a new drug is on the horizon It’s been six years...
Read MoreSep 1, 2020
PARALLAX finds biomarker benefit for ARNI, but fails to show functional benefit Heart failure with...
Read More